Doctors across Europe face a growing challenge in treating serious hospital infections as common bacteria develop resistance to essential antibiotics, according to a report from the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC). The report reveals that in half of the European countries surveyed, over 50% of samples from hospitals showed resistance to crucial antibiotics.
The organizations are calling for immediate action from European countries to combat antimicrobial resistance. Health professionals are increasingly relying on broad-spectrum beta-lactam antibiotics, as standard treatments become ineffective against formerly manageable bacterial infections.
Standard Antibiotic Treatments are Failing
Data from 2025 indicates troubling trends in antibiotic resistance among two hospital-associated bacteria, Klebsiella pneumoniae and Acinetobacter. In 21 out of 43 reporting countries, over half of the Klebsiella pneumoniae samples were resistant to third-generation cephalosporins, commonly used antibiotics. As conventional treatments fail, doctors are turning to carbapenems, which are typically reserved for severe cases.
However, resistance to these carbapenems is also rising, with 10 of the reporting countries finding that half or more of the Klebsiella pneumoniae bacteria were resistant. The situation with Acinetobacter mirrors this trend, appearing in 21 of 38 reporting countries.
Dr. Marc-Alain Widdowson, Programme Manager for Health Security Division at WHO/Europe, emphasized the critical nature of antibiotics as a line of defense against serious infections. He stated, “When doctors’ first antibiotics fail, the next option is often a stronger drug that isn’t always readily available.” He warned that patients whose initial treatments are unsuccessful face a higher risk of mortality.
European Countries Missed Targets
Despite efforts to combat this issue, progress appears to be stagnating. Two out of three targets established by the EU to diminish bloodstream infections caused by resistant bacteria by 2030 are now further from being met than in 2019. Cases of carbapenem-resistant Klebsiella pneumoniae surged by an estimated 75% from 2019 to 2025, contradicting the goal of a 5% reduction. Similarly, resistance in E. coli, the most frequent cause of bloodstream infections in the EU, increased by 16.4%, falling short of the 10% decrease target.
There is some positive news; the incidence of resistant Acinetobacter infections has dropped nearly 50% since 2021, yet the situation remains precarious with inconsistent data collection across countries.
WHO/Europe Calls for Action
Although most countries in the WHO European Region have established national action plans to address antimicrobial resistance or are in the process of revising them, only 40% are actually implementing these plans with adequate funding and regular progress checks. WHO/Europe urges nations to prioritize funding and execution of these strategies while maintaining vigilant monitoring.
The organization advocates for infection prevention in hospitals as a critical measure to curtail the spread of antibiotic resistance. WHO/Europe also recommends judicious use of antibiotics, reserving powerful last-resort options for necessary cases.
Investment in laboratories capable of identifying resistance patterns is essential for future preparedness. Dr. Widdowson called for urgent and effective action, stating, “A plan on paper may exist, but it does not stop infections in a hospital ward.” Countries must ensure that patients have access to necessary last-resort antibiotics when required.


